Cargando…

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives

Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical syndromes. Systemic treatment of patients with unresectable NETs aims to control symptoms related to hormonal overproduction an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera-Martínez, Aura D., Hofland, Johannes, Hofland, Leo J., Brabander, Tessa, Eskens, Ferry A. L. M., Gálvez Moreno, María A., Luque, Raúl M., Castaño, Justo P., de Herder, Wouter W., Feelders, Richard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338796/ https://www.ncbi.nlm.nih.gov/pubmed/30560479 http://dx.doi.org/10.1007/s40265-018-1033-0

Ejemplares similares

Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells
por: Herrera-Martínez, Aura D., et al.
Publicado: (2019)

Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients
por: Refardt, Julie, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours
por: Blažević, Anela, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women
por: Blažević, Anela, et al.
Publicado: (2022)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
por: Hofland, Johannes, et al.
Publicado: (2020)

Epigenetic regulation of SST(2) expression in small intestinal neuroendocrine tumors
por: Klomp, Maria J., et al.
Publicado: (2023)

Induction therapy with (177)Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients
por: Minczeles, Noémie S., et al.
Publicado: (2022)

Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis in small intestinal neuroendocrine tumors
por: Blažević, Anela, et al.
Publicado: (2022)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Radionuclide therapy in the time of COVID-19
por: Brabander, Tessa, et al.
Publicado: (2020)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells
por: Veenstra, Marije J., et al.
Publicado: (2016)

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
por: Minczeles, N.S., et al.
Publicado: (2021)

What’s new on the HPA axis?
por: Hofland, Johannes, et al.
Publicado: (2015)

Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment
por: Cuny, Thomas, et al.
Publicado: (2022)

Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation
por: Hofland, Johannes, et al.
Publicado: (2014)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors
por: Herrera-Martínez, Aura D., et al.
Publicado: (2018)

Sarcopenia and Ghrelin System in the Clinical Outcome and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Herrera-Martínez, Yiraldine, et al.
Publicado: (2021)

New Directions in Imaging Neuroendocrine Neoplasms
por: Refardt, Julie, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase
por: Hofland, Johannes, et al.
Publicado: (2013)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy
por: Ebbers, Sander C., et al.
Publicado: (2022)

Future treatment strategies of aggressive pituitary tumors
por: Lamberts, Steven W. J., et al.
Publicado: (2008)

How to Differentiate Benign from Malignant Adrenocortical Tumors?
por: Viëtor, Charlotte L., et al.
Publicado: (2021)

Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors
por: van Adrichem, R C S, et al.
Publicado: (2013)

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors
por: Pedraza‐Arevalo, Sergio, et al.
Publicado: (2021)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line
por: Bresciani, Giulia, et al.
Publicado: (2019)

Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
por: Dietvorst, Maria H. P., et al.
Publicado: (2013)

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
por: Beukhof, Carolien M., et al.
Publicado: (2019)

The role of mTOR pathway as target for treatment in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Fluorescence-guided surgery using methylene blue to improve identification of metastatic small intestinal neuroendocrine tumours
por: Galema, Hidde A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vbjbkpga0nb6h5e09v1ls56tlv